BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
8.55
0.00 (0.00%)
At close: Jul 25, 2025, 4:00 PM
8.55
0.00 (0.02%)
After-hours: Jul 25, 2025, 6:41 PM EDT

BioCryst Pharmaceuticals Stock Forecast

Stock Price Forecast

The 10 analysts that cover BioCryst Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $16.7, which forecasts a 95.32% increase in the stock price over the next year. The lowest target is $11 and the highest is $30.

Price Target: $16.7 (+95.32%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$11$16.7$17$30
Change+28.65%+95.32%+98.83%+250.88%

Analyst Ratings

The average analyst rating for BioCryst Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingFeb '25Mar '25Apr '25May '25Jun '25Jul '25
Strong Buy222223
Buy334566
Hold111111
Sell000000
Strong Sell000000
Total6678910

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
B of A Securities
B of A Securities
Strong Buy
Maintains
$13$15
Strong BuyMaintains$13$15+75.44%Jul 1, 2025
RBC Capital
RBC Capital
Buy
Reiterates
$13
BuyReiterates$13+52.05%Jun 30, 2025
Wedbush
Wedbush
Buy
Maintains
$16$18
BuyMaintains$16$18+110.53%Jun 30, 2025
Needham
Needham
Strong Buy
Reiterates
$17
Strong BuyReiterates$17+98.83%Jun 27, 2025
Needham
Needham
Strong Buy
Reiterates
$17
Strong BuyReiterates$17+98.83%Jun 25, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
624.23M
from 450.71M
Increased by 38.50%
Revenue Next Year
686.88M
from 624.23M
Increased by 10.04%
EPS This Year
0.11
from -0.43
EPS Next Year
0.49
from 0.11
Increased by 334.66%
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
17.81M157.17M270.83M331.41M450.71M624.23M686.88M764.76M
Revenue Growth
-63.53%782.38%72.32%22.37%36.00%38.50%10.04%11.34%
EPS
-1.09-1.03-1.33-1.18-0.430.110.490.68
EPS Growth
------334.66%37.76%
Forward PE
-----75.7617.4312.65
No. Analysts
-----151512
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High661.4M775.7M895.7M
Avg624.2M686.9M764.8M
Low588.1M603.1M595.0M

Revenue Growth

Revenue Growth20252026202720282029
High
46.7%
24.3%
30.4%
Avg
38.5%
10.0%
11.3%
Low
30.5%
-3.4%
-13.4%

EPS Forecast

EPS20252026202720282029
High0.370.891.22
Avg0.110.490.68
Low0.030.210.27

EPS Growth

EPS Growth20252026202720282029
High-
684.3%
148.3%
Avg-
334.7%
37.8%
Low-
82.4%
-44.1%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.